Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR-TREC
2024-516106-31-00Phase 3Authorised
- Sponsor
- University of Birmingham
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised trial of capecitabine in rectal cancer (2 arms), sponsored by University of Birmingham. Primary endpoints: Recruitment rate and Successful organ preservation. Planned start Nov 2024; status: authorised.
02
Drugs
capecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2024-516106-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516106-31-00.